Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 30 Neoplasms 11 Thyroid Neoplasms 7 Thyroid Carcinoma, Anaplastic 6 Brain Neoplasms 6 Multiple Myeloma 4 Glioma 4 Colorectal Neoplasms 4 Hematologic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Thyroid Cancer, Papillary 2 Skin Neoplasms 2 Neoplasm Metastasis 2 Lymphoma 2 Glioblastoma 2 Astrocytoma 2 Ameloblastoma 2 Adenocarcinoma, Follicular 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Rectal Neoplasms 1 Rare Malignant Neoplasm 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Malignant Neoplasm × dabrafenib × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡